Biotech 365

Main menu

Skip to primary content
Skip to secondary content
  • Biotech 365
    • Contact
    • Offers
  • Biotech Companies
  • Database researchers
    • BioLeads
  • BioMarketplace
  • Biotech Jobs
  • Biopharma News

Tag Archives: Joe Senesac

Bellicum – dendritic cell vaccines

Posted on 2015-05-01 by Biotech365

Bellicum Pharmaceuticals is a biopharma company developing novel cellular immunotherapies for various forms of cancer (both hematological and solid tumors), as well as orphan inherited blood disorders.

Bellicum – dendritic cell vaccines

Bellicum Continue reading →

Posted in Biotech Companies, Biotech Companies USA | Tagged activation switch, Alan Musso, Annemarie Moseley, Bellicum, Bellicum - dendritic cell vaccines, Bellicum Pharmaceuticals, BPX-201, BPX-401, BPX-501, BPX-601, BPX-701, cancer immunotherapies, cancer immunotherapy, CAR T cell therapy, CaspaCIDe, CD40, cellular immunotherapies, cellular immunotherapy, Chemical Induction Dimerization, Chemical Induction of Dimerization, CID, CIDeCAR, David Spencer, DeCIDe, dendritic cell, dendritic cell therapies, dendritic cell therapy, dendritic cell vaccine, dendritic cell vaccines, dendritic cells, dual co-stimulatory domain, Frank McGuyer, GoCAR-T, hematological tumor, hematological tumors, hematopoietic stem cell transplantation, HSCT, immunotherapies, immunotherapy, James Brown, Joe Senesac, Jon Stonehouse, Ken Moseley, Kevin Slawin, MyD88, orphan inherited blood disorder, orphan inherited blood disorders, Peter Hoang, Reid Huber, rimiducid, safety switch, solid tumor, solid tumors, Thomas Farrell, Tom Farrell
Contact                       Offers                      
Proudly powered by WordPress